Surfactant treatment for acute respiratory distress syndrome
نویسندگان
چکیده
منابع مشابه
Surfactant treatment for acute respiratory distress syndrome.
OBJECTIVE To determine prospectively the efficacy of surfactant in acute respiratory distress syndrome. STUDY DESIGN Twenty patients, 1 month to 16 years of age, diagnosed with an acute pulmonary disease with severe hypoxaemia (PaO2/FiO2 < 100) (13 with systemic or pulmonary disease and seven with cardiac disease) were treated with one to six doses of 50-200 mg/kg of porcine surfactant admini...
متن کاملSurfactant medication for acute respiratory distress syndrome.
Background. Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant. Surfactant replacement improves physiologic function in such patients, and preliminary data suggest that it may improve survival. Methods. We conducted a prospective, multicenter, double-blind, randomized, placebo-controlled trial involving 725 patients with sepsis-induced ARDS. Patients were s...
متن کاملChoosing a right surfactant for respiratory distress syndrome treatment.
Respiratory distress syndrome (RDS) is the most common cause of respiratory insufficiency in preterm infants, especially those born at <30 weeks of gestation. Continuous positive airway pressure has been used since the 1970s as a primary mode of treatment for RDS. Surfactant therapy became available in the 1980s and has become the standard care for infants with or at risk for RDS. Surfactant th...
متن کاملTreatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant.
We performed a phase I/II trial in North America of a recombinant surfactant protein C-based surfactant (Venticute) as treatment for the acute respiratory distress syndrome. Patients were prospectively randomized to receive either standard therapy or standard therapy plus one of two doses of exogenous surfactant given four times over 24 hours. Surfactant administration was well tolerated. No si...
متن کاملExogenous surfactant in acute respiratory distress syndrome: more is better.
Pulmonary surfactant is a complex of highly active phospholipids and proteins that cover the alveolar epithelial surface of the lungs [1]. Surfactant is synthesized in the alveolar type-II cells, stored in the lamellar bodies, and secreted to the alveolar space where it undergoes complex changes [2]. The composition of lung surfactant in humans is very constant, although it may change in diseas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Disease in Childhood
سال: 1999
ISSN: 0003-9888,1468-2044
DOI: 10.1136/adc.80.3.248